Skip to content

Released Aug 5, 2025, before the open

10-Q filed Aug 5, 2025, 36 days after period end · 0001628280-25-037606

Q2 2025 · 10-Q
Revenue$7.56M+9.7% vs Q2 2024+27.0% vs Q1 2025
Net Income-$17.94MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.28N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$21,097,000N/M
Operating Cash Flowderived-$21,000,000N/M
Free Cash Flowderived-$21,022,000N/M
Margins · derived
Operating margin-279.2%+107.5 pt vs Q2 2024
Net margin-237.3%+96.3 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$7.56M$6.89M$5.60M$4.49M
Net Income-$17.94M-$22.98M-$29.49M-$27.31M
EPS Diluted-$0.28-$0.45-$0.70-$0.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR